Selected article for: "inflammatory response and lung damage"

Author: Yin Wang; Weiwei Jiang; Qi He; Cheng Wang; Baoju Wang; Pan Zhou; Nianguo Dong; Qiaoxia Tong
Title: Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China
  • Document date: 2020_3_12
  • ID: 23mp5961_23
    Snippet: For the patients of severe COVID-19 pneumonia, aggravation of symptoms always occurs during 5-7 days after onset [13] . Therefore, it is important to strengthen the treatment for suppression of pro-inflammatory response and control of cytokine storm at this stage. A majority of patients can survival and recover if they overcome this period. Corticosteroid are the classical immunosuppressive drugs, which are important to stop or delay the progress.....
    Document: For the patients of severe COVID-19 pneumonia, aggravation of symptoms always occurs during 5-7 days after onset [13] . Therefore, it is important to strengthen the treatment for suppression of pro-inflammatory response and control of cytokine storm at this stage. A majority of patients can survival and recover if they overcome this period. Corticosteroid are the classical immunosuppressive drugs, which are important to stop or delay the progression of the pneumonia and have been proved to be effective for treatment of ARDS [14, 15] . In addition to immunosuppressive activities, corticosteroid have an anti-inflammatory role to reduce systemic inflammatory, decrease exudative fluid in the lung tissue, promote absorption of inflammasome and prevent further diffuse alveolar damage, which can relieve hypoxemia and effectively protect the lung to prevent further progression of respiratory insufficiency [16] .

    Search related documents:
    Co phrase search for related documents